XVIVO.ST
Xvivo Perfusion AB (publ) [XVIVO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XVIVO.ST Stock Summary
Top 10 Correlated Stocks
XVIVO.ST
In the News
XVIVO.ST Financial details
Company Rating
Buy
Market Cap
10.19B
Income
91.82M
Revenue
597.54M
Book val./share
61.75
Cash/share
17.34
Dividend
-
Dividend %
-
Employees
160
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
416.79
Forward P/E
-
PEG
11.06
P/S
18.3
P/B
5.21
P/C
18.31
P/FCF
210
Quick Ratio
4.18
Current Ratio
6.15
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
2.96
EPS next Y
-
EPS next Q
-
EPS this Y
395.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
74.45%
Revenue last 5Y
22.03%
Revenue Q/Q
6.22%
EPS Q/Q
2762.8%
-
-
-
-
SMA20
11.4%
SMA50
10.23%
SMA100
20.08%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
2%
ROC
0.01%
Gross Margin
74%
Oper. Margin
4%
Profit Margin
4%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
205.5-343.5
52W High
-7.43%
52W Low
+54.88%
RSI
63.22
Rel Volume
0.18
Avg Volume
66.35K
Volume
12.16K
Perf Week
12.99%
Perf Month
18.91%
Perf Quarter
40.18%
Perf Half Y
31.74%
-
-
-
-
Beta
2.094
-
-
Volatility
14.26%, 19.44%
Prev Close
-3.2%
Price
317.5
Change
-2.16%
XVIVO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.33 | 6.62 | 8.96 | 14.07 | 19.96 | |
| Net income per share | 0.19 | -1.61 | 0.28 | 0.62 | 3.07 | |
| Operating cash flow per share | 1.11 | -0.45 | -0.42 | 0.94 | 1.55 | |
| Free cash flow per share | -2.04 | -2.83 | -3.68 | -3.49 | -3.26 | |
| Cash per share | 6 | 13.01 | 13.82 | 8.35 | 18.24 | |
| Book value per share | 21.78 | 37.11 | 44.56 | 48.44 | 64.98 | |
| Tangible book value per share | 9.01 | 14.13 | 12.48 | 8.53 | 24.21 | |
| Share holders equity per share | 21.78 | 37.11 | 44.56 | 48.44 | 64.98 | |
| Interest debt per share | 0.22 | 0.28 | 0.21 | 0.36 | 1.09 | |
| Market cap | 4.51B | 8.53B | 8.03B | 5.4B | 9.86B | |
| Enterprise value | 4.35B | 8.19B | 7.64B | 5.17B | 9.65B | |
| P/E ratio | 912.77 | -195.08 | 985.47 | 293.22 | 107.42 | |
| Price to sales ratio | 20.41 | 47.44 | 31.09 | 13.01 | 16.51 | |
| POCF ratio | 152.79 | -695.57 | -666.19 | 193.97 | 213.1 | |
| PFCF ratio | -83.19 | -110.88 | -75.69 | -52.41 | -101.01 | |
| P/B Ratio | 7.81 | 8.46 | 6.25 | 3.78 | 5.07 | |
| PTB ratio | 7.81 | 8.46 | 6.25 | 3.78 | 5.07 | |
| EV to sales | 19.72 | 45.51 | 29.57 | 12.44 | 16.15 | |
| Enterprise value over EBITDA | 142.81 | -481.76 | 194.72 | 79.06 | 139.1 | |
| EV to operating cash flow | 147.59 | -667.34 | -633.6 | 185.48 | 208.46 | |
| EV to free cash flow | -80.36 | -106.38 | -71.99 | -50.12 | -98.81 | |
| Earnings yield | 0 | -0.01 | 0 | 0 | 0.01 | |
| Free cash flow yield | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | |
| Debt to equity | 0.01 | 0.01 | 0 | 0.01 | 0.02 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Net debt to EBITDA | -5.04 | 20.38 | -10.01 | -3.62 | -3.09 | |
| Current ratio | 4.94 | 6.41 | 5.24 | 3.47 | 6.14 | |
| Interest coverage | 19.76 | -95.05 | 25.3 | 38.32 | 32.36 | |
| Income quality | 5.58 | 0.21 | -1.81 | 1.25 | 0.5 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0.4 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.17 | 0.22 | 0.17 | 0.13 | |
| Research and developement to revenue | 0.28 | 0.31 | 0.21 | 0.17 | 0.22 | |
| Intangibles to total assets | 0.53 | 0.54 | 0.6 | 0.68 | 0.56 | |
| Capex to operating cash flow | -2.84 | 5.27 | 7.8 | -4.7 | -3.11 | |
| Capex to revenue | -0.38 | -0.36 | -0.36 | -0.32 | -0.24 | |
| Capex to depreciation | -3.37 | -2.15 | -2.92 | -3.11 | -4.66 | |
| Stock based compensation to revenue | 0.03 | 0.1 | 0.01 | 0.02 | 0 | |
| Graham number | 9.55 | 36.66 | 16.83 | 26.08 | 66.96 | |
| ROIC | 0.01 | -0.03 | 0.01 | 0.01 | 0.02 | |
| Return on tangible assets | 0.02 | -0.08 | 0.01 | 0.03 | 0.09 | |
| Graham Net | 6.07 | 10.09 | 7.91 | 2.54 | 15.2 | |
| Working capital | 207.29M | 390.98M | 443.01M | 332.61M | 691.92M | |
| Tangible asset value | 239.01M | 383.81M | 360.01M | 251.82M | 724.69M | |
| Net current asset value | 202.92M | 321.38M | 290.39M | 164.56M | 575.84M | |
| Invested capital | 0.01 | 0.01 | 0 | 0.01 | 0.02 | |
| Average receivables | 24.56M | 46.41M | 53.81M | 84.09M | 111.32M | |
| Average payables | 15.37M | 14.44M | 17.96M | 29.96M | 37.26M | |
| Average inventory | 40.13M | 51.61M | 68.47M | 92.08M | 124.09M | |
| Days sales outstanding | 81.17 | 88.68 | 90.28 | 91.63 | 72.31 | |
| Days payables outstanding | 90.62 | 112.63 | 111.65 | 118.66 | 72.85 | |
| Days of inventory on hand | 275.97 | 462.04 | 403.96 | 328.7 | 286.14 | |
| Receivables turnover | 4.5 | 4.12 | 4.04 | 3.98 | 5.05 | |
| Payables turnover | 4.03 | 3.24 | 3.27 | 3.08 | 5.01 | |
| Inventory turnover | 1.32 | 0.79 | 0.9 | 1.11 | 1.28 | |
| ROE | 0.01 | -0.04 | 0.01 | 0.01 | 0.05 | |
| Capex per share | -3.16 | -2.38 | -3.26 | -4.43 | -4.81 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.44 | 4.71 | 5.17 | 4.86 | 4.94 | |
| Net income per share | 0.02 | 0.48 | 0.23 | 0.08 | 2.17 | |
| Operating cash flow per share | 0.74 | -0.42 | 0.53 | 0.82 | 0.58 | |
| Free cash flow per share | 0.6 | -0.76 | 0.3 | 0.61 | 0.58 | |
| Cash per share | 8.33 | 6.64 | 5.74 | 19.72 | 17.34 | |
| Book value per share | 48.31 | 48.5 | 50.33 | 63.97 | 61.75 | |
| Tangible book value per share | 8.51 | 8.37 | 8.67 | 22.6 | 23.01 | |
| Share holders equity per share | 48.31 | 48.5 | 50.33 | 63.97 | 61.75 | |
| Interest debt per share | 0.32 | 9.64 | 9.29 | 0.99 | 1 | |
| Market cap | 5.42B | 7.28B | 9.07B | 8.27B | 10.38B | |
| Enterprise value | 5.18B | 7.37B | 9.18B | 7.7B | 10.16B | |
| P/E ratio | 1.85K | 128.37 | 329.16 | 905.56 | 37.89 | |
| Price to sales ratio | 41.19 | 51.77 | 58.65 | 56.43 | 66.64 | |
| POCF ratio | 248.63 | -585.74 | 575.75 | 333.06 | 572.58 | |
| PFCF ratio | 305.99 | -320.28 | 1.02K | 451.1 | 572.58 | |
| P/B Ratio | 3.79 | 5.03 | 6.03 | 4.29 | 5.34 | |
| PTB ratio | 3.79 | 5.03 | 6.03 | 4.29 | 5.34 | |
| EV to sales | 39.39 | 52.44 | 59.39 | 52.55 | 65.27 | |
| Enterprise value over EBITDA | 275.37 | 657.98 | 2.41K | 1.45K | 2.25K | |
| EV to operating cash flow | 237.77 | -593.39 | 582.96 | 310.16 | 560.73 | |
| EV to free cash flow | 292.63 | -324.46 | 1.04K | 420.09 | 560.73 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.01 | 0.2 | 0.19 | 0.01 | 0.02 | |
| Debt to assets | 0.01 | 0.17 | 0.16 | 0.01 | 0.01 | |
| Net debt to EBITDA | -12.57 | 8.48 | 29.89 | -107.27 | -47.61 | |
| Current ratio | 3.47 | 3.31 | 3.77 | 6.15 | 6.14 | |
| Interest coverage | -5.15 | -2.09 | -0.5 | 1.22 | 0 | |
| Income quality | 7.92 | -0.75 | 1.38 | 26.04 | 0.26 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.18 | 0.14 | 0.18 | 0.09 | 0.11 | |
| Research and developement to revenue | 0.18 | 0.19 | 0.2 | 0.19 | 0.21 | |
| Intangibles to total assets | 0.68 | 0.69 | 0.7 | 0.56 | 0.56 | |
| Capex to operating cash flow | -0.19 | 0.83 | -0.44 | -0.26 | 0 | |
| Capex to revenue | -0.03 | -0.07 | -0.04 | -0.04 | 0 | |
| Capex to depreciation | -0.36 | -0.83 | -0.51 | -0.48 | 0 | |
| Stock based compensation to revenue | 0.05 | 0 | 0 | 0 | 0 | |
| Graham number | 5.19 | 22.77 | 16.16 | 10.44 | 54.96 | |
| ROIC | 0 | 0.01 | 0 | 0.01 | -0.01 | |
| Return on tangible assets | 0 | 0.03 | 0.01 | 0 | 0.07 | |
| Graham Net | 2.54 | 1.99 | 1.69 | 15.21 | 14.45 | |
| Working capital | 332.61M | 307.55M | 317.08M | 731.55M | 691.92M | |
| Tangible asset value | 251.82M | 249.69M | 258.96M | 681.05M | 724.69M | |
| Net current asset value | 164.56M | 147.87M | 146.35M | 564.63M | 575.84M | |
| Invested capital | 0.01 | 0.2 | 0.19 | 0.01 | 0.02 | |
| Average receivables | 102.84M | 118.3M | 134.35M | 135.05M | 126.06M | |
| Average payables | 60.34M | 81.37M | 114.46M | 118.63M | 84.33M | |
| Average inventory | 98.28M | 108.56M | 117.1M | 134.64M | 143.61M | |
| Days sales outstanding | 71.35 | 84.71 | 79.39 | 82.1 | 68.41 | |
| Days payables outstanding | 94.45 | 312.41 | 240.82 | 305.9 | 47.89 | |
| Days of inventory on hand | 261.64 | 277.93 | 284.55 | 335.9 | 188.08 | |
| Receivables turnover | 1.26 | 1.06 | 1.13 | 1.1 | 1.32 | |
| Payables turnover | 0.95 | 0.29 | 0.37 | 0.29 | 1.88 | |
| Inventory turnover | 0.34 | 0.32 | 0.32 | 0.27 | 0.48 | |
| ROE | 0 | 0.01 | 0 | 0 | 0.04 | |
| Capex per share | -0.14 | -0.35 | -0.23 | -0.22 | 0 |
XVIVO.ST Frequently Asked Questions
What is Xvivo Perfusion AB (publ) stock symbol ?
Xvivo Perfusion AB (publ) is a SE stock and trading under the symbol XVIVO.ST
What is Xvivo Perfusion AB (publ) stock quote today ?
Xvivo Perfusion AB (publ) stock price is $317.5 today.
Is Xvivo Perfusion AB (publ) stock public?
Yes, Xvivo Perfusion AB (publ) is a publicly traded company.
Company Profile
- Volume Average 66.35K
- Market Capitalization 10.19B
- Employee 160
- CEO Mr. Christoffer Rosenblad
- Headquarters Gothenburg,SE
- IPO Date 2012-10-08
-
Website
https://www.xvivoperfusion.com 
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
